

New Drug, Generic, and Biosimilar Pipeline Report

Q4 2025

Below is a summary of significant upcoming drug launches for newly approved brand drugs, generics, and biosimilars.

New Drug Pipeline

GENERIC NAME	BRAND NAME Manufacturer if drug name unavailable	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Plozasiran	(Arrowhead)	Subcutaneous	November 2025	\$300,000 - \$500,000 annually	Cardiovascular	Specialty
Carbidopa, levodopa	(NeuroDerm)	Subcutaneous	Q4 2025	\$85,000 - \$120,000 annually	Parkinson's Disease	Traditional
Semaglutide	(Novo Nordisk)	Oral	Q4 2025	\$15,000 - \$20,000 annually	Endocrine: Obesity	Traditional
Imlunestrant	(Eli Lilly)	Oral	Q4 2025	\$200,000 - \$300,000 annually	Oncology	Specialty
Ziftomenib	(Kura Oncology)	Oral	Q4 2025	\$300,000 - \$500,000 annually	Oncology	Specialty
Nerandomilast	Boehringer Ingelheim	Oral	Q4 2025	\$100,000 - \$200,000 annually	Pulmonology	Specialty
Depemokimab	(GSK)	Subcutaneous	Q4 2025	\$50,000 - \$100,000 annually	Pulmonology	Specialty
Brensocaticb	Insmed	Oral	Q4 2025	\$50,000 - \$100,000 annually	Pulmonology	Specialty
Rilzabrutinib	Sanofi	Oral	Q4 2025	\$100,000 - \$300,000 annually	Hematology	Specialty

Generic Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS / EST LOE PROB	ESTIMATED 2024 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Linagliptin; Metformin	Jentaduo XR	Oral	November 2025	38	Endocrine: Diabetes	Traditional
Linagliptin	Tradjenta	Oral	November 2025	1,445	Endocrine: Diabetes	Traditional
Tabentadol	Nucynta	Oral	November 2025	177	Pain	Traditional
Gabapentin enacarbil	Horizant	Oral	2025	102	Pain	Traditional
Gabapentin enacarbil	Horizant	Oral	2025	102	Pain	Traditional
Carbidopal levodopa	Rytary	Oral	2025	352	Parkinson's Disease	Traditional
Raltegravir	Isentress	Oral	2025	263	Antiretroviral	Traditional
Azelaic acid	Finacea Foam	Topical	2025	31	Dermatology	Traditional
Ipratropium bromide	Atrovent HFA	Inhaler	2025	224	Pulmonology	Traditional
Treprostinil	Tyvaso	Inhaler	January 2026	728	Cardiovascular	Traditional
Brivaracetam	Briviact	Oral	February 2026	818	Epilepsy	Traditional
Pomalidomide	Pomalyst	Oral	March 2026	3,206	Oncology	Traditional
Metformin; Sitagliptin	Janumet	Oral	May 2026	1,354	Endocrine: Diabetes	Traditional
Sitagliptin	Januvia	Oral	May 2026	6,397	Endocrine: Diabetes	Traditional

Biosimilar Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED 2024 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Bosutinib	Bosulif	Oral	2025	654	Oncology	Biosimilar
Avtozma SC Tocilizumab Celltrion IV Tocilizumab Fresenius IV Tocilizumab Celltrion SC Tocilizumab Fresenius SC	Acterna	Subcutaneous	2025	2,221	Autoimmune	Biosimilar
Aukelso Denosumab Fresenius Xbryk	Xgeva	Subcutaneous	2026	2,134	Osteoporosis	Biosimilar
Bosaya Denosumab Fresenius Denosumab Samsung Bioepis Ospomyv	Prolia	Subcutaneous	2026	4,317	Osteoporosis	Biosimilar
Nintedanib	Ofev	Oral	April 2026	2,979	Pulmonology	Biosimilar
Tofacitinib Citrate	Xeljanz	Oral	Q2 2026	4,304	Autoimmune	Biosimilar
Omlyclo Omalizumab Celltrion	Xolair	Subcutaneous	2026	3,904	Autoimmune	Biosimilar
Starjemza Ustekinumab Alvotech IV	Stelara	Subcutaneous	2026	22,367	Autoimmune	Biosimilar

Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.

*New Formulation of an Existing Product

Source: IPD Analytics, 2025

ServeYouRx.com | 800-759-3203

